COVID-19 in rheumatic patients: a prospective cohort study

Recruiting

Conditions: All systemic autoimmune diseases

Registration Number: NL-OMON26858

Lead Sponsor: Reade Research BV

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 8000

Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Age = 18 years.

For patients:
- Diagnosed by their treating physician with a systemic autoimmune disease.

For controls:
- Belonging to family or close friend of patient (of the same gender).

Exclusion Criteria

Patients who meet the following criteria will be excluded from the study:
- Language problems precluding the completion of the questionnaire;
- Likelihood of absence in the next 6 months;
- Lack of informed consent.

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Our primary study parameter is the percentage of participants with a positive IgM or IgG response admitted to the hospital.

Secondary Outcome Measures

Name	Time	Method
Other parameters include:<br>- The percentage of participants with a positive IgM or IgG response admitted to the ICU, and mortality due to SARS-CoV-2;<br>- The geometric mean antibody titre over time;<br>- The geometric mean and incidence of different antibody profiles (IgM/G/A, IgG1/3) and repertoire (anti-SP, anti-NP);<br>- The geometric mean antibody avidity;<br>- The percentage of patients who changed the dosage or use of their DMARD;<br>- Mean rheumatic disease activity.